TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26445094
Drug: nab-paclitaxel (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-paclitaxel (125 mg/m²) plus gemcitabine (1000 mg/m²) given on days 1, 8, and 15 every 28 days
Study: 26445094
Drug: nab-paclitaxel (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-paclitaxel (125 mg/m²) plus sLV5FU2 (leucovorin 400 mg/m² followed by bolus 400 mg/m² 5-fluorouracil and by 5-fluorouracil 2400 mg/m² as an 46-h intravenous infusion) given on days 1 and 15 every 28 days
Study: 23825656
Drug: Condition A
Normalized name: CONDITION AND ENHANCE SYSTEM TRAVEL-SIZE SURGICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Condition A (continuous transdermal alcohol monitoring anklet, no alcohol consumption for 14 days)
Study: 20670293
Drug: Tigecycline (TGC)
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tigecycline (TGC) 100 mg initial dose followed by 50 mg every 12 h
Study: 20670293
Drug: Ceftriaxone (CTX)
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftriaxone (CTX) 2 g once daily plus Metronidazole (MET) 1-2 g daily
Study: 12811360
Drug: Methotrexate (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (low dose, 6 oral doses of 30 mg/m2; high dose, 1 g/m2 intravenously) followed by intravenous mercaptopurine (1 g/m2 over a 6-hour period)
Study: 12811360
Drug: Mercaptopurine alone
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mercaptopurine alone (1 g/m2 over a 6-hour period)
Study: 1893906
Drug: 3 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg.kg‐1 body weight of caffeine (C3)
Study: 1893906
Drug: 5 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg.kg‐1 body weight of caffeine (C5)
Study: 1893906
Drug: gelatin capsule
Normalized name: Gelatin Capsules
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gelatin capsule (C)
Study: 1893906
Drug: C3 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: C3 and C5 treatments
Study: 29391380
Drug: Protein-enriched, milk-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-enriched, milk-based supplements (27.5 g whey protein/day)
Study: 29391380
Drug: Isoenergetic placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoenergetic placebo products (<1.5 g protein/day)
Study: 27590454
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser treatment at auriculotherapy points
Study: 23935745
Drug: Porcine acellular
Normalized name: porcine acellular small intestine submucosa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porcine acellular dermal xenograft (ADX) in combination with autologous split‐thickness skin grafting
Study: 18495806
Drug: Valproate (Depakine‐Chrono)
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate (Depakine‐Chrono) 3000 mg/day
Study: 17168254
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lithium and T3
Study: 8996846
Drug: i.v. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusion of adrenaline (1 microgram/min)
Study: 8996846
Drug: i.v. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusion of isoprenaline (1 microgram/min)
Study: 8996846
Drug: i.v. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusion of isoprenaline (1 microgram/min) with pretreatment with 100 mg talinolol
Study: 8996846
Drug: p.o. administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: p.o. administration of 1200 mg celiprolol
Study: 8996846
Drug: p.o. administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: p.o. administration of 0.4 mg bimakalim
Study: 8996846
Drug: p.o. administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: p.o. administration of PDE-III inhibitors meribendan and isomazole
Study: 2088025
Drug: Oral etretinate
Normalized name: etretinate
DrugBank: Etretinate (DB00926)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral etretinate
Study: 29095358
Drug: Oral spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral spironolactone treatment
Study: 29984418
Drug: Unguided internet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unguided internet cognitive-behavioral treatment (ICBT) for perfectionism
Study: 26242288
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg menthol
Study: 26242288
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg nicotine + 30 mg menthol
Study: 12937858
Drug: Oral suspension
Normalized name: Oral Suspension
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral suspension of megestrol acetate (MA) at a daily dose of 480-840 mg
Study: 12937858
Drug: Oral suspension
Normalized name: Oral Suspension
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral suspension of megestrol acetate (MA)
Study: 11732527
Drug: Placebo (Intralipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Intralipid 1 ml h(‐1))
Study: 3066417
Drug: Sublingual lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual lorazepam
Study: 6136288
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) lorazepam
Study: 30401369
Drug: Opsite combined
Normalized name: DRESSING,OPSITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opsite combined with wet gauze and eye ointment (ointment group)
Study: 24444360
Drug: Umbilical vein
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umbilical vein injection of 800 mcg misoprostol dissolved in 20 mL of normal saline
Study: 24444360
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving 20 mL of normal saline
Study: 17711616
Drug: Current asthma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current asthma therapy (control)
Study: 15966467
Drug: Glimepiride/Specifar (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride/Specifar (test preparation)
Study: 12472990
Drug: Local antibiotic
Normalized name: RECTAL,LOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local antibiotic therapy combined with scaling and root planing
Study: 8589139
Drug: Intravenous Immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Immunoglobulin (IVIG) prophylaxis
Study: 31628486
Drug: COMBO (continuing
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMBO (continuing csDMARD therapy)
Study: 31628486
Drug: MONO (withdrawing
Approvals — FDA: no, EMA: no, PMDA: no
Description: MONO (withdrawing csDMARD therapy)
Study: 19474512
Drug: R-CHOP therapy
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP therapy (rituximab combined with cyclophosphamide, doxorubicin, vincristine, and predonisolone)
Study: 17265094
Drug: HES preload
Normalized name: HE-2200
DrugBank: HE-2200 (DB06257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES preload group (15 ml x kg(‐1) before spinal anesthesia, n = 18)
Study: 17265094
Drug: HES coload
Normalized name: HE-2200
DrugBank: HE-2200 (DB06257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES coload group (15 ml x kg(‐1) after induction of spinal anesthesia, n = 18)
Study: 17265094
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no rapid infusion, n = 18)
Study: 11739069
Drug: Bupropion sustained-release
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion sustained-release (100 mg-300 mg/day)
Study: 11739069
Drug: Paroxetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (10 mg-40 mg/day)
Study: 10195027
Drug: Patient Delivered
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient Delivered Partner Medication (PDPM)
Study: 7842362
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 200 micrograms aqueous nasal spray twice daily
Study: 7842362
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo spray
Study: 3170392
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily dose of netilmicin plus metronidazole
Study: 3170392
Drug: Thrice daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice daily dose of netilmicin plus metronidazole
Study: 24737406
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group (UPPP + Oral Appliance)
Study: 23161360
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml ropivacaine 0.75% plus 20 µg dexmedetomidine (RpD)
Study: 23161360
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml ropivacaine 0.75% (R)
Study: 23161360
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml ropivacaine 0.75% plus systemic 20 µg dexmedetomidine (RsD)
Study: 21574873
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of l-arginine (0.075 g·kg(‐1) of body mass)
Study: 21574873
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of l-arginine (0.15 g·kg(‐1) of body mass)
Study: 21574873
Drug: Low and
Normalized name: ZINC OXIDE 88 mg in 1 mL TOPICAL LOTION [Ciele Glow and Protect]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low and High dose of l-arginine
Study: 17027233
Drug: Konjac glucomannan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Konjac glucomannan (KGM) 1.5 g/meal, 4.5 g/d for 21 days
Study: 15617456
Drug: telmisartan 40
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: telmisartan 40 mg once daily
Study: 9928753
Drug: enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 10 mg once daily
Study: 8328575
Drug: Triazolam plus
Normalized name: Triazolam
DrugBank: Triazolam (DB00897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triazolam plus behavioral therapy
Study: 3016071
Drug: Control (NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (NaCl infusion study)
Study: 31640921
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) therapy
Study: 22527984
Drug: Folate <5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folate <5 ug/L
Study: 22527984
Drug: 25‐hydroxy vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25‐hydroxy vitamin D <20 ng/mL
Study: 21275160
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine and general stroke-treatment (135 patients)
Study: 21275160
Drug: General stroke-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: General stroke-treatment only (126 patients)
Study: 18848094
Drug: Propofol (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (administered by OMS)
Study: 18848094
Drug: Propofol (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (administered by non-OMS)
Study: 16096449
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine gel, three times a day during the entire ICU stay
Study: 16096449
Drug: Placebo gel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel, three times a day during the entire ICU stay
Study: 12045487
Drug: Tenofovir DF
Normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir DF 300 mg once-daily
Study: 12045487
Drug: Tenofovir DF
Normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir DF 300 mg therapy
Study: 1326582
Drug: Intranasal interferon‐alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal interferon‐alpha 2b, ipratropium, and oral naproxen; treatment started 24 hours after inoculation, continued three times a day for 4 days
Study: 29676237
Drug: Ultramicronized palmitoylethanolamide
Normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultramicronized palmitoylethanolamide (600 mg twice daily)
Study: 29676237
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment except surgical therapy)
Study: 12878631
Drug: Oxygen 50%
Normalized name: Nitrous oxide 50% and oxygen 50% gas for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen 50% administration during surgery and for 2 h post-surgery
Study: 12878631
Drug: Oxygen 30%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen 30% administration during surgery and for 2 h post-surgery
Study: 12878631
Drug: Oxygen 50%
Normalized name: Nitrous oxide 50% and oxygen 50% gas for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen 50% administration
Study: 12878631
Drug: Oxygen 30%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen 30% administration
Study: 10388309
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of contrast material (iopamidol 300 mgI/ml)
Study: 10388309
Drug: 50 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml of contrast material (iopamidol 300 mgI/ml)
Study: 30796194
Drug: Zoledronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoledronate (10 courses of 4 mg intravenous infusions)
Study: 29043927
Drug: Novel proprietary
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel proprietary curcumin liquid droplet micromicellar formulation (CLDM), 400 mg dose, containing 64.6 mg curcumin
Study: 29043927
Drug: 95% curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 95% curcumin powder in capsule form, 400 mg dose, containing 323 mg curcumin
Study: 27692279
Drug: Intravenous normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous normal saline infusion as a bolus of 22 ml/kg body weight (approximately 2 L)
Study: 27692279
Drug: Control: intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: intravenous normal saline infusion at a minimal rate to keep the vein open
Study: 25148841
Drug: Date palm
Normalized name: date palm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Date palm pollen (DPP) administered orally (2 g daily for 42 days)
Study: 10815850
Drug: Experimental bicarbonate
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental bicarbonate solution
Study: 8751396
Drug: Conformal neutron/photon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conformal neutron/photon irradiation with neoadjuvant hormonal therapy
Study: 8751396
Drug: Conformal neutron/photon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conformal neutron/photon irradiation without neoadjuvant hormonal therapy
Study: 29902979
Drug: 5% imiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% imiquimod cream, applied intravaginally three times a week for 16 weeks.
Study: 29902979
Drug: Large Loop
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large Loop Excision of the Transformation Zone (LLETZ) treatment, performed according to current guidelines.
Study: 26841373
Drug: Single intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intramuscular injection of 0.03 mg rhTSH
Study: 23015069
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose approach (3 mg/day)
Study: 17655682
Drug: Desmopressin MELT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin MELT (sublingual lyophilisate)
Study: 17655682
Drug: Tablet formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet formulation of desmopressin
Study: 12665498
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg micronized fenofibrate daily
Study: 1906160
Drug: Cefprozil (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefprozil (30 mg/kg/day divided into two equal doses)
Study: 1906160
Drug: Amoxicillin clavulanate
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin clavulanate potassium (40 mg/kg/day divided into three equal doses)
Study: 1906160
Drug: Amoxicillin clavulanate
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin clavulanate potassium
Study: 6137601
Drug: Aldose reductase
Normalized name: Aldose reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldose reductase inhibitor ('Sorbinil'‐‐Pfizer CP 45, 634)
Study: 23052819
Drug: Abduction splint
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abduction splint treatment compliance
Study: 15816472
Drug: Antioxidant biofactor
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant biofactor AOB (3x2 sachets of 3 g powder each for 3 months)
Study: 15816472
Drug: Conventional antiviral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional antiviral treatment (pegylated interferon alpha and ribavirin) after 3 months
Study: 6369669
Drug: High-dose steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose steroids with azathioprine
Study: 6369669
Drug: Low-dose steroids
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose steroids with azathioprine
Study: 16536341
Drug: Adper Prompt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adper Prompt L‐Pop (APLP)
Study: 16536341
Drug: Prompt L‐Pop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt L‐Pop 2 (PLP)
Study: 3521518
Drug: Oral bacitracin
Normalized name: Bacitracin
DrugBank: Bacitracin (DB00626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral bacitracin
Study: 26379068
Drug: HIV-1 Gag-
Normalized name: GAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1 Gag- and Nef-transfected DCs (vaccine)
Study: 21275332
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (MT) sessions multiple times per week
Study: 12941198
Drug: Recent advances
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recent advances in biologic response modifier therapy
Study: 10230954
Drug: Amrinone (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrinone (loading dose of 2 mg/kg, maintenance infusion of 7.5 microg/kg/min)
Study: 8674002
Drug: Second-line hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second-line hormonal therapy with megestrol acetate or fadrozole
Study: 1688356
Drug: Ambroxol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol (1 g/day intravenously for 6 consecutive days)
Study: 7017343
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion at a rate of 0.33 mU/kg/min
Study: 7017343
Drug: No insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No insulin infusion (control)
Study: 31553457
Drug: NKTR-181 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKTR-181 400 mg
Study: 31553457
Drug: NKTR-181 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKTR-181 600 mg
Study: 31553457
Drug: NKTR-181 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKTR-181 400 mg and 600 mg
Study: 20386884
Drug: Oxycodone 40
Normalized name: ibuprofen-oxycodone 400 mg-5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 40 mg
Study: 29265090
Drug: Tolpersione injection
Normalized name: tolperisone
DrugBank: Tolperisone (DB06264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolpersione injection and oral formulations combined with NSAID
Study: 29265090
Drug: NSAID monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID monotherapy
Study: 25453481
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose exercise regimen
Study: 25453481
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose exercise regimen
Study: 18637782
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of enteric-coated aspirin tablets daily
Study: 14998110
Drug: Medication management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication management (MedMgt)
Study: 15060224
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Comb)
Study: 15060224
Drug: Behavior modification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior modification therapy (Beh)
Study: 15060224
Drug: Usual community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual community comparison (CC)
Study: 11753057
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection with rehabilitation
Study: 11753057
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection with rehabilitation
Study: 8480506
Drug: Isradipine (0.0010,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (0.0010, 0.0020, 0.0040, 0.0080 mg.kg‐1; total 0.0150 mg.kg‐1)
Study: 8480506
Drug: Verapamil (0.0125,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (0.0125, 0.0250, 0.0500, 0.1000 mg.kg‐1; total 0.1875 mg.kg‐1)
Study: 22367114
Drug: Rebamipide (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebamipide (15 mg, t.i.d. for 4 weeks)
Study: 20162245
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose dobutamine infusion
Study: 17192164
Drug: Ramelteon (melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon (melatonin receptor agonist)
Study: 17192164
Drug: Benzodiazepine and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine and nonbenzodiazepine sedative-hypnotic agents